Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

6171 - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Wojciech Szopa


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


W. Szopa1, P. Czekaj2, K. Malarz3, A. Mrozek-Wilczkiewicz3, D. Plewka2, M. Niedbała1, M. de Mezer4, G. Kramer-marek5, W. Kaspera6

Author affiliations

  • 1 Department Of Neurosurgery, Regional Hospital, Medical University of Silesia, 41-200 - Sosnowiec/PL
  • 2 Histology And Embryology, Medical University of Silesia, 40-752 - Medyków/PL
  • 3 Silesian Centre For Education And Interdisciplinary Research, University of Silesia, Chorzow/PL
  • 4 Center For Advanced Technology, Adam Mickiewicz University, 61-614 - Poznan/PL
  • 5 Radiotherapy And Imaging, The Institute of Cancer Research (Sutton Site), SM2 5NG - Sutton/GB
  • 6 Department Of Neurosurgery, Regional Hospital, Medical University of Silesia, Sosnowiec/PL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 6171


Clinical trials using immune checkpoint inhibitors (ICPIs) against immune inhibitory receptor ligand 1 (PD-L1) have failed to show clinical benefit for glioblastoma (GBM) patients. This is likely due to multiple factors, including but not limited to, the immunologically cold GBM microenvironment lacking effector immune cells. PD-L1 expression in tumour cells can be regulated by epidermal growth factor receptor/janus kinase 2 (EGFR/JAK2) signalling that might weaken the antitumor immune response by increasing PD-L1 level. Furthermore, EGFR is mutationally activated in approximately 50% of GBMs. Therefore, we analysed changes in EGFR and PD-L1 expression levels in the intraoperative specimens obtained from patients diagnosed with primary GBMs.


In total, 27 patients with newly diagnosed GBM underwent surgery and were investigated for mRNA and protein expression level either of Ki67, EGFR/EGFRvIII and PD-L1 by quantitative reverse transcription-PCR (qRT-PCR) or immunohistochemistry (IHC).


EGFR overexpression (IHC H-score > 200 [0-300]) was detected in 8/27(30%) specimens as assessed by IHC, whereas 25/27 samples (93%) showed increased EGFR mRNA expression, suggesting a higher sensitivity of qRT-PCR analysis. Of the 25, 10 patients were harbouring EGFRvIII mutation. PD-L1 protein expression (2+ and 3+ staining in > 5% cells) was present in 16/27(60%) samples, of which concurrent elevation of PD-L1 and EGFR mRNA copy numbers was seen in 9/16 samples. In contrast, IHC revealed EGFR overexpression in only 2/16 PDL-1 positive patients. Ki67 staining revealed great variety in proliferation status of the GBMs, with a median Ki67 index of 30 (range 10-62).


Collectively, these results confirm that primary GBMs are characterised by a considerable heterogeneity of EGFR, EGFRvIII and PD-L1 expressions at both mRNA and protein levels. The PD-L1 mRNA expression was found to be associated with EGFR mRNA copy number only in small group of patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


NCNOPUS13#2017/25/B/NZ5/00039, KNW-1-108/N/8/O.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.